Lacosamide API

Xi'an Faithful BioTech Co., Ltd: Your Trusted Lacosamide API Manufacturer & Supplier

ADD 243037 is a new NMDA receptor glycine site binding antagonist, which belongs to a new class of functional amino acids. Clinical trials show that it is an anticonvulsant product with a brand-new dual mechanism. In addition, the Lacosamide API powder provided by Xi'an Faithful BioTech Co., Ltd. can selectively promote the slow inactivation of sodium channels and regulate the collapse response-mediated protein -2 (CRMP-2), which is currently confirmed to be very effective in slowing down or even preventing seizures and alleviating neuropathic pain of diabetes.

Lacosamide Introduction

Lacosamide API is a functional amino acid. Unlike traditional AEDs, which exert antiepileptic effects by enhancing the rapid inactivation of voltage-gated sodium channels, Lacoamide is the first third-generation novel AED that selectively enhances the slow inactivation of sodium ion channels. On experimental white mice, we can clearly observe that high-quality Lacosamide powder selectively promotes the slow inactivation of sodium channels, which helps normalize the activation threshold, reduce the pathophysiological activity of neurons, and thereby control the excessive excitability of neurons.
Clinical application results show that at relevant concentrations, lacoamide inhibits repetitive discharges of neurons by selectively enhancing the slow inactivation of sodium channels, thereby reducing the long-term availability of active sodium channels without affecting normal physiological activities. It belongs to the currently popular adjuvant treatment products used for partial seizures of epilepsy caused by any reason.

Specifications

Why Choose Us? 

In the field of antiepileptic drugs, Erlosamide API , as a selective slow-inactivated sodium channel blocker, has become the first-line drug for treating focal epileptic seizures worldwide due to its outstanding efficacy and safety. With the continuous growth of the global market and the constant emergence of generic drugs, the demand for high-quality, high-purity and stable supply of Lacosamide API is becoming increasingly urgent.
When you are committed to developing Lacosamide API powder, a reliable API partner is the cornerstone of your project's success. The following are our advantages and the core reasons why we look forward to establishing a long-term cooperative relationship with you:
1.Unparalleled purity and quality assurance
Exceeding pharmacopoeia standards: Our Lacosamide API not only strictly complies with major global pharmacopoeia standards such as USP/EP/ChP, but we have also established internal control standards within the enterprise, which are more stringent in controlling key impurities (such as related substances, residual solvents), ensuring the safety and efficacy of your final formulation products from the source.
Comprehensive quality system: We follow cGMP (Good Manufacturing Practice) and ICH guidelines to establish a quality management system that covers the entire process from research and development, production, quality inspection to storage and transportation. Each batch of Harkoseride API is accompanied by a detailed Analysis Certificate (COA) to ensure its identity, purity, quality and traceability.
2. Strong large-scale production capacity and stable supply
Ensuring supply chain security: We possess advanced production facilities and mature synthesis processes, and have the capacity for large-scale and continuous production ranging from kilograms to tons. This means that whether your demand is a small sample in the R&D stage or a large order for commercial production, we can deliver on time and in full quantity, eliminating the risk of supply chain disruption for you.
Process optimization and cost control: Through continuous process optimization and technological innovation, our synthetic routes are efficient, environmentally friendly and cost-effective. This enables us to offer you highly competitive market prices, helping your formulation products gain an edge in the market.
3. Profound technical expertise and regulatory support
Not only suppliers, but also technical partners: Our team is composed of experienced chemists, pharmacologists and regulatory experts. We are well-versed in the synthesis difficulties, crystal form research and stability challenges of SPM 927 powder. We can offer you in-depth technical support, including customizing specifications, solving technical problems and sharing the latest research data.
Seamless regulatory document support: To help you complete the drug registration application more quickly, we can provide comprehensive, accurate and compliant drug master documents (DMF) or CEP (European Pharmacopoeia Certificate of Conformity) and other regulatory support documents, significantly shortening your approval cycle.​​​​​​​
4. Outstanding customer service and cooperation experience
Prompt and personalized service: From the moment you send your first inquiry, we will assign you a dedicated business and technical manager to provide one-on-one service and respond quickly to any technical and business issues you may have.
Flexible cooperation model: We understand that each customer's needs are unique. Whether it is a long-term strategic cooperation or a flexible custom synthesis project, we are willing to discuss with you to find the most suitable cooperation plan and achieve a win-win situation.

Please contact us via the following email address to start our cooperation journey.

Email: sales8@faithfulbio.com

Advantages

1. It is not metabolized by the liver
The pharmacokinetic characteristics of lacoamide include rapid absorption, a direct ratio of plasma concentration to dose within the approved dose range (the maximum approved therapeutic dose in China is 400 mg/d), no induction or inhibition of cytochrome P450 enzymes, and a relatively low binding rate to plasma proteins (<15%).
Blood oxygen monitoring revealed that it could reach the maximum blood drug concentration within 1 to 4 hours, with an elimination half-life of approximately 13 hours and a steady-state blood drug concentration after 3 days. It is mainly eliminated through excretion by the kidneys and biotransformation.

2. There are almost no drug interactions
Due to the low plasma protein binding rate of lacoamide and its non-inductive or inhibitory effect on cytochrome P450 enzymes, it has no clinically significant drug interactions with common products. For instance, lacoamide API has no significant effect on the blood drug concentration of other AEDs.

Quality Control:

Packaging and Transportation:

After-Sales Service: 

Qualification Certification:

Transaction Feedback: 

Exhibition: 

look forward to your presence:

Act now to raise the benchmark of your Lacosamide API research.
If you need product documentation, COA or request samples, please contact our research support team directly.

Contact email: sales8@faithfulbio.com

Faithful Bio - Empowering Innovation, Precise Protection